Abstract
Background: The bacterium Helicobacter pylori (H. pylori) is known to cause gastroduodenal
disorders associated with the stomach lining that grows in the gastrointestinal tract, and can
cause gastritis, peptic ulcer, gastric lymphoma, and stomach cancer. Nearly 50% of people worldwide
suffer from H. pylori infection. This infection is more prominent in poor nations and undeveloped
countries, and is caused by multiple factors, such as consumption of unhygienic food, crowded living
style, etc. In the eradication treatment of gastric H. pylori infection, conventional dosage forms have
various adverse effects on patients.
Methods: In this study, we have explored current developments in the utilization of nanotechnological
carriers for the successful management of
H. pylori infection. In order to combat rising amoxicillin resistance,
this review has focused on therapeutic strategies that use cyclodextrins, niosomes, liposomes,
microspheres, nanoparticles, solid lipid nanoparticles, and nanostructure nanoparticles to improve
therapy against
H. pylori.
Results: The entrapment of amoxicillin in various nanotechnological carriers enhances its effectiveness
and reduces adverse effects. These carriers lead to targeted drug release and improve drug penetration
to the gastroduodenal disease site that locally controls and adjusts the drug release.
Conclusion: For the effective treatment of
H. pylori infection, nanotechnological carriers have provided
a new avenue for the development of innovative, high-impact, and low-dose systems. The main objective
of this review was to outline the present limitations of
H. pylori therapy and new potential alternatives,
as well as to report how nanotechnological carriers may be used to overcome treatment
shortcomings.
Graphical Abstract
[22]
Miller, M.A.; Kuemmerle, N.B.; Gentile, G. Amoxycillin and ampicillin. A comparative study of in vitro sensitivity and induced morpho-logical alterations in Serratiamarcescens. Jpn. J. Microbiol., 1975, 19(3), 219-224.
[73]
Onuigibo, E.B.; Eze, J.; Attama, A.A. Functional properties of amoxicillin encapsulated in noisome or liposome. African J. Pharm. Rese. Devel., 2015, 7(2), 66-71.
[74]
Sharma, N.; Purwar, N.; Gupta, P.C. Microsphere as drug carriers for control drug delivery: A review. Int. J. Pharmaceut Sci. Res., 2022, 6(11), 4579-4587.
[83]
Chen, Y. Nanoparticles-A review. Trop. J. Pharmares., 2006, 5(1), 561-573.
[97]
Henry, H. Modified release amoxicillin product. U.S. Patent 8,778,924 B2, 2014.
[98]
Rajinder, K. Micronized amoxicillin. U.S. Patent 9,820,943 B2, 2017.
[99]
Alejandro, H. Pediatric oral suspension formulation of Amoxicillin and Clavulanate Potassium and methods for using same. U.S. Patent 2020/0330441 A1, 2020.
[100]
Ma, H. Amoxicillin dispersible tablet and preparation method thereof. C.N. Patent 109394718 B, 2021.
[101]
Ma, J.; Chen, M. Amoxicillin soluble powder and preparation method thereof. C.N. Patent 113304112A, 2018.
[102]
Xing, F. A kind of preparation method of amoxil capsule. C.N. Patent 109953971A, 2019.
[103]
Xu, H. High water-soluble Amoxicillin and preparation method thereof. C.N. Patent 109867687B, 2021.
[104]
Huang, G. Preparation method of sterile Amoxicillin. C.N. Patent 113577317A, 2021.
[105]
Xu, D. Amoxicillin capsules preparation method and amoxicillin capsule. C.N. Patent 112156082A, 2021.
[106]
Lu, X. Preparation method and application of high-content amoxicillin soluble powder. C.N. Patent 105726487B, 2020.
[107]
Cui, X. Amoxicillin soluble powder easy to dissolve in water and high in stability and preparation method thereof. C.N. Patent 111529493A, 2020.
[108]
Dai, Y. Compound amoxicillin soluble powder and preparation method thereof. C.N. Patent 110711193A, 2020.
[109]
Lu, C. Alkalescent amoxicillin soluble powder and preparation method thereof. C.N. Patent CN112587481B, 2022.